<DOC>
	<DOC>NCT02617095</DOC>
	<brief_summary>The purpose of this study is to compare the efficacy and safety of T2762 versus Optive® in the treatment of moderate to severe Dry Eye Syndrome.</brief_summary>
	<brief_title>Comparison of the Efficacy and Safety of T2762 Versus Optive® in the Treatment of Moderate to Severe Dry Eye Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<criteria>Signed and dated informed consent. Male or female aged ≥ 18 years old. Diagnosis of moderate to severe dry eye syndrome Pregnancy, lactation. Childbearing potential woman who is not using a reliable method of contraception and is not surgically sterilised. Inability of patient to understand the study procedures and thus inability to give informed consent. Noncompliant patient Participation in another clinical study at the same time as the present study. Participation to the present study during the exclusion period of another clinical study. Already included once in this study. Ward of court. Patient not covered by government health care scheme</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>